Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study.

ABSTRACT:

Introduction

Cenobamate (CNB) is a novel antiseizure medication (ASM) approved as an add-on therapy for drug-resistant focal onset seizures. Although its mechanism of action is not fully understood, CNB enhances inhibitory GABAergic transmission and blocks voltage-gated sodium channels. Its non-linear pharmacokinetics and strong modulation of cytochrome P450 enzymes may significantly affect the metabolism of co-administered ASMs, posing important challenges for polytherapy management. This retrospective study, complemented by prospective follow-up evaluations, aimed at elucidating, in a cohort of subjects enrolled in an Italian multicenter study, the following: i) the CNB dose associated with clinical response; ii) inter-individual variability in CNB plasma concentrations (CNBp); i

SUBMITTER: Operto FF 

PROVIDER: S-EPMC12497770 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature